G31.83 Dementia with Lewy bodies

Name of the Condition

• Dementia with Lewy bodies

Summary

Dementia with Lewy bodies (DLB) is a progressive neurodegenerative disorder characterized by cognitive decline, visual hallucinations, and motor symptoms. It involves abnormal protein deposits (Lewy bodies) in the brain, leading to impairments in thinking, movement, and behavior. DLB shares features with both Alzheimer’s disease and Parkinson’s disease but has distinct clinical and pathological profiles.

Causes

The exact cause of DLB is not fully understood, but it is associated with the accumulation of alpha-synuclein protein in neurons, forming Lewy bodies. Genetic factors may play a role, though most cases are sporadic. Environmental or age-related factors may contribute to disease development, but no single cause is universally identified.

Risk Factors

• Age: Higher prevalence in older adults, typically over 50.
• Sex: Slightly more common in males.
• Family history: A history of DLB or Parkinson’s disease may increase risk.
• Coexisting conditions: Parkinsonism or REM sleep behavior disorder may precede or coexist with DLB.

Symptoms

• Fluctuating cognition (e.g., attention, alertness)
• Visual hallucinations (often detailed and persistent)
• Parkinsonism (e.g., bradykinesia, rigidity, tremor)
• REM sleep behavior disorder (vivid dreams, physical acting out)
• Autonomic dysfunction (e.g., blood pressure changes, urinary issues)

Diagnosis

Diagnosis is based on clinical evaluation, including history, neurological exams, and assessment of cognitive and motor symptoms. Imaging (e.g., MRI, PET scans) may help rule out other conditions. Response to dopaminergic medications and exclusion of other dementias are key considerations. No single test confirms DLB, but specific criteria guide diagnosis.

Treatment Options

• Symptomatic management: Cholinesterase inhibitors (e.g., rivastigmine) for cognitive symptoms; carbidopa-levodopa for motor symptoms.
• Non-pharmacologic: Physical therapy, occupational therapy, and environmental modifications.
• Monitoring: Regular assessment for falls, autonomic issues, and psychiatric symptoms (e.g., depression, anxiety).

Prognosis and Follow-Up

DLB is progressive, with symptoms worsening over time. Life expectancy varies but is generally shorter than in Alzheimer’s disease. Regular follow-up is essential to manage symptoms, adjust treatments, and address complications (e.g., infections, mobility issues). Multidisciplinary care (neurologists, psychiatrists, therapists) is often recommended.

Complications

• Increased risk of falls and injuries due to motor impairment.
• Severe autonomic dysfunction (e.g., orthostatic hypotension, urinary incontinence).
• Psychiatric symptoms (e.g., depression, psychosis) that may require intervention.
• Higher susceptibility to infections, especially with advanced disease.

Lifestyle & Prevention

• Maintain a safe environment to reduce fall risk (e.g., remove tripping hazards).
• Engage in regular, supervised physical activity to support mobility.
• Follow a balanced diet and stay hydrated to support overall health.
• Encourage social interaction and cognitive stimulation to preserve function.

When to Seek Professional Help

Seek care if cognitive or motor symptoms worsen rapidly, hallucinations become distressing, or autonomic issues (e.g., dizziness, incontinence) develop. Prompt evaluation is important if new psychiatric symptoms (e.g., agitation, paranoia) emerge or if falls or injuries occur.

Tips for Medical Coders

Document the presence of core DLB features (cognitive fluctuations, visual hallucinations, Parkinsonism) to support code assignment. Note any associated conditions (e.g., REM sleep behavior disorder) or comorbidities that may impact coding. Ensure clinical documentation aligns with diagnostic criteria to justify the use of G31.83.